Your browser doesn't support javascript.
loading
Intravenous Dosing as an Alternate Approach to Safely Achieve Supratherapeutic Exposure for Assessments of Cardiac Repolarization: A Randomized Clinical Trial with Mavoglurant (AFQ056).
Ufer, Mike; Sagkriotis, Alexandros; Salunke, Atish; Ganesan, Subramanian; Tisserant, Anne; Dodman, Angela; Voltz, Emilie; Woessner, Ralph; Jordaan, Pierre; Legangneux, Eric.
Afiliação
  • Ufer M; Novartis Pharma AG, Basel, Switzerland. Electronic address: mike.ufer@novartis.com.
  • Sagkriotis A; Novartis Pharma AG, Basel, Switzerland.
  • Salunke A; Novartis Healthcare Pvt Ltd, Hyderabad, India.
  • Ganesan S; Novartis Healthcare Pvt Ltd, Hyderabad, India.
  • Tisserant A; Novartis Pharma AG, Basel, Switzerland.
  • Dodman A; Novartis Pharma AG, Basel, Switzerland.
  • Voltz E; Novartis Pharma AG, Basel, Switzerland.
  • Woessner R; Novartis Pharma AG, Basel, Switzerland.
  • Jordaan P; Novartis Pharma AG, Basel, Switzerland.
  • Legangneux E; Novartis Pharma AG, Basel, Switzerland.
Clin Ther ; 38(12): 2589-2597, 2016 Dec.
Article em En | MEDLINE | ID: mdl-27823869
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptor de Glutamato Metabotrópico 5 / Coração / Indóis Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Adult / Humans / Male Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptor de Glutamato Metabotrópico 5 / Coração / Indóis Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Adult / Humans / Male Idioma: En Ano de publicação: 2016 Tipo de documento: Article